Maria Isabel S Gouvea1,2, Esau C Joao1, Maria de Lourdes B Teixeira1,2, Jennifer S Read3, Sergio E L Fracalanzza4, Claudia T V Souza2, Maria José de Souza5, Helio M Torres Filho6, Cassiana C F Leite6, Pedro E A A do Brasil2. 1. a Infectious Diseases Department, Hospital Federal dos Servidores do Estado , Rio de Janeiro , Brazil. 2. b Instituto Nacional de Infectologia Evandro Chagas - Fiocruz , Rio de Janeiro , Brazil. 3. c Department of Epidemiology and Biostatistics , University of California at San Francisco , San Francisco , CA , USA. 4. d Laboratório de Bacteriologia Médica do Instituto de Microbiologia Prof. Paulo de Góes , Universidade Federal do Rio de Janeiro , Rio de Janeiro , Brazil. 5. e Department of Bacteriology , Hospital Federal dos Servidores do Estado , Rio de Janeiro , Brazil , and. 6. f Laboratório Richet , Núcleo de Apoio à Pesquisa Clínica , Rio de Janeiro , Brazil.
Abstract
OBJECTIVE: There are limited data regarding Xpert performance to detect Group B Streptococcus (GBS) in HIV-infected pregnant women. We evaluated the accuracy of a rapid real-time polymerase chain reaction (PCR) test in a cohort of HIV-infected women. METHODS: At 35-37 weeks of pregnancy, a pair of combined rectovaginal swabs were collected for two GBS assays in a cohort of sequentially included HIV-infected women in Rio de Janeiro: (1) culture; and (2) real-time PCR assay [GeneXpert GBS (Cepheid, Sunnyvale, CA)]. Using culture as the reference, sensitivity, specificity, positive and negative-likelihood ratios were estimated. RESULTS: From June 2012 to February 2015, 337 pregnant women met inclusion criteria. One woman was later excluded, due to failure to obtain a result in the index test; 336 were included in the analyses. The GBS colonization rate was 19.04%. Sensitivity and specificity of the GeneXpert GBS assay were 85.94% (95% CI: 75.38-92.42) and 94.85% (95% CI: 91.55-96.91), respectively. Positive and negative predictive values were 79.71% (95% CI: 68.78-87.51) and 96.63% (95% CI: 93.72-98.22), respectively. CONCLUSIONS: GeneXpert GBS is an acceptable test for the identification of GBS colonization in HIV-infected pregnant women and represents a reasonable option to detect GBS colonization in settings where culture is not feasible.
OBJECTIVE: There are limited data regarding Xpert performance to detect Group B Streptococcus (GBS) in HIV-infected pregnant women. We evaluated the accuracy of a rapid real-time polymerase chain reaction (PCR) test in a cohort of HIV-infectedwomen. METHODS: At 35-37 weeks of pregnancy, a pair of combined rectovaginal swabs were collected for two GBS assays in a cohort of sequentially included HIV-infectedwomen in Rio de Janeiro: (1) culture; and (2) real-time PCR assay [GeneXpert GBS (Cepheid, Sunnyvale, CA)]. Using culture as the reference, sensitivity, specificity, positive and negative-likelihood ratios were estimated. RESULTS: From June 2012 to February 2015, 337 pregnant women met inclusion criteria. One woman was later excluded, due to failure to obtain a result in the index test; 336 were included in the analyses. The GBS colonization rate was 19.04%. Sensitivity and specificity of the GeneXpert GBS assay were 85.94% (95% CI: 75.38-92.42) and 94.85% (95% CI: 91.55-96.91), respectively. Positive and negative predictive values were 79.71% (95% CI: 68.78-87.51) and 96.63% (95% CI: 93.72-98.22), respectively. CONCLUSIONS: GeneXpert GBS is an acceptable test for the identification of GBS colonization in HIV-infected pregnant women and represents a reasonable option to detect GBS colonization in settings where culture is not feasible.
Entities:
Keywords:
Culture; HIV; group B Streptococcus; real-time polymerase chain reaction
Authors: S M Morrissey; M Nielsen; L Ryan; H Al Dhanhani; M Meehan; S McDermott; N O'Sullivan; M Doyle; P Gavin; N O'Sullivan; R Cunney; R J Drew Journal: Eur J Clin Microbiol Infect Dis Date: 2017-03-01 Impact factor: 3.267